710 582

Cited 0 times in

치료방법이 미분화 갑상선암의 생존 기간에 미치는 효과

DC Field Value Language
dc.contributor.author김경래-
dc.contributor.author김소헌-
dc.contributor.author안철우-
dc.contributor.author이유미-
dc.contributor.author임승길-
dc.date.accessioned2017-10-26T06:38:06Z-
dc.date.available2017-10-26T06:38:06Z-
dc.date.issued2005-
dc.identifier.issn2093-596X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/151107-
dc.description.abstractBackground : Anaplastic thyroid carcinoma represents 2% to 5% of all thyroid cancers and it is one of the most aggressive human cancers. Local extension at the time of diagnosis and distant metastases are almost always the rule. Its lethality is evidenced by a 5-year survival rate of 3.6% and a median survival time of 4 months. We retrospectively reviewed patients with this disease at 4 tertiary referral centers. Methods : From 1990 to 2003, 19 cases (9 men and 10 women, mean age: 65.1 ± 7.1 years) of anaplastic thyroid carcinoma were reviewed via the medical records. The overall survival rates according to the prognostic factors and the treatment modalities were analyzed. Results : The presenting symptoms included rapidly enlarged neck masses in 16 patients, shortness of breath in 3 patients, hoarseness in 4 patients, dysphagia in 2 patients and chest wall pain in 1 patient. The mean diameter of tumor was 7.2 cm. Local extension was seen in all of the cases that had undergone surgery. Distant metastases (lung 6, bone 2, abdominal carcinomatosis 2, brain 1 and mediastinum 1) were seen in 9 patients. Surgical treatment was performed in 10 patients. Radiotherapy was performed in 9 patients and chemotherapy was done in 5 patients; radiotherapy was performed alone in 2 patients, combination chemo-radiotherapy was performed in 3 patients, postoperative radiotherapy was performed in 2 patients and postoperative combination chemo-radiotherapy was performed in 2 patients. 4 patients were treated cons ervatively after the confirmative diagnosis. The overall median survival time was 123 days (range: 23~621 days); the median survival time was 129 days in the treatment group (n=15), and 27 days in the no treatment group (n=4), and significantly higher survival rates were observed for the treated patients (p=0.02). According to the treatment modalities, patients who underwent surgical treatment and postoperative radiotherapy and/or chemotherapy were observed to have significantly higher survival rates than patients in the radiotherapy and/or chemotherapy group (p=0.03), and also than those patients in the surgical treatment only group (p=0.04). Conclusion : We found that aggressive surgical treatment and postoperative radiotherapy and/or chemotherapy improved the survival rates of patients with anaplastic thyroid carcinoma even though local invasion and distant metastases was generally observed to occur.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Endocrine Society-
dc.relation.isPartOfEndocrinology and Metabolism (대한내분비학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnaplastic thyroid carcinoma-
dc.subject.MESHSurgery-
dc.subject.MESHTreatment modalities-
dc.subject.MESHTreatment outcome-
dc.title치료방법이 미분화 갑상선암의 생존 기간에 미치는 효과-
dc.title.alternativeThe Effect of Treatment Modalities on Survival Rates of Patients with?Anaplastic Thyroid Carcinoma-
dc.typeArticle-
dc.publisher.locationKorea-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJae Myoung Choi-
dc.contributor.googleauthorMi Jeong Kim-
dc.contributor.googleauthorSeung Won Lee-
dc.contributor.googleauthorKyoung Eun Song-
dc.contributor.googleauthorYoon-Sok Chung-
dc.contributor.googleauthorKwan Woo Lee-
dc.contributor.googleauthorDae Jung Kim-
dc.contributor.googleauthorSung Hee Choi-
dc.contributor.googleauthorSo Hun Kim-
dc.contributor.googleauthorMin Ho Cho-
dc.contributor.googleauthorYumie Rhee-
dc.contributor.googleauthorChul Woo Ahn-
dc.contributor.googleauthorSung Kil Lim-
dc.contributor.googleauthorKyung Rae Kim-
dc.identifier.doi10.3803/jkes.2005.20.2.127-
dc.contributor.localIdA00294-
dc.contributor.localIdA00624-
dc.contributor.localIdA02270-
dc.contributor.localIdA03012-
dc.contributor.localIdA03375-
dc.relation.journalcodeJ00773-
dc.identifier.eissn2093-5978-
dc.relation.journalsince2011~-
dc.identifier.pmid10.3803/jkes.2005.20.2.127-
dc.relation.journalbefore~2010 Journal of Korea Society of Endocrinology (대한내분비학회지)-
dc.subject.keywordAnaplastic thyroid carcinoma-
dc.subject.keywordSurgery-
dc.subject.keywordTreatment modalities-
dc.subject.keywordTreatment outcome-
dc.contributor.alternativeNameKim, Kyung Rae-
dc.contributor.alternativeNameKim, So Hun-
dc.contributor.alternativeNameAhn, Chul Woo-
dc.contributor.alternativeNameRhee, Yumie-
dc.contributor.alternativeNameLim, Sung Kil-
dc.citation.volume20-
dc.citation.number2-
dc.citation.startPage127-
dc.citation.endPage133-
dc.identifier.bibliographicCitationEndocrinology and Metabolism (대한내분비학회지), Vol.20(2) : 127-133, 2005-
dc.date.modified2017-05-04-
dc.identifier.rimsid43450-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.